CLINICAL TRIALS PROFILE FOR OLODATEROL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for OLODATEROL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01153711 ↗ | Relative Bioavailability of of Olodaterol and Ketoconazole | Completed | Boehringer Ingelheim | Phase 1 | 2010-05-01 | This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol |
| NCT01153724 ↗ | Relative Bioavailability of Olodaterol and Fluconazole | Completed | Boehringer Ingelheim | Phase 1 | 2010-05-01 | This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol |
| NCT01311661 ↗ | A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma | Completed | Boehringer Ingelheim | Phase 2 | 2011-03-01 | This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose). |
| NCT01428622 ↗ | Olodaterol Bridging Study in Asthma | Withdrawn | Boehringer Ingelheim | Phase 2 | 2011-10-01 | The aim of the study is to establish the olodaterol dose in the ethanolic fixed dose combination (FDC) with BI 54903 which is equivalent in bronchodilator effect and systemic exposure to the 5 µg olodaterol reference dose in the aqueous inhalation solution (AIS). |
| NCT01431274 ↗ | Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 3 | 2011-09-01 | The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD). |
| NCT01431287 ↗ | Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 3 | 2011-09-01 | The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OLODATEROL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for OLODATEROL HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for OLODATEROL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for OLODATEROL HYDROCHLORIDE
Sponsor Name
